Breakthrough in Obesity Fight: Revolutionary Oral Treatment Shows Promising Results in Early-Stage Study
- Terns Pharmaceuticals has announced a breakthrough in its oral obesity treatment, with early-stage studies demonstrating safety, tolerability, and significant weight loss effects.
- The results of the study, released on September 9th, revealed that participants who took 740 mg of TERN-601 once a day for four weeks experienced an average weight...
- TERN-601 is an experimental oral weight loss drug, also being developed by pharmaceutical giants Pfizer and Roche.
Tuns’ Oral Obesity Treatment Shows Promise in Early-Stage Research
Terns Pharmaceuticals has announced a breakthrough in its oral obesity treatment, with early-stage studies demonstrating safety, tolerability, and significant weight loss effects.
The results of the study, released on September 9th, revealed that participants who took 740 mg of TERN-601 once a day for four weeks experienced an average weight loss of 4.9%.
TERN-601 is an experimental oral weight loss drug, also being developed by pharmaceutical giants Pfizer and Roche. Unlike injectable weight loss medications currently on the market, such as Novo Nordisk’s Wigovi and Eli Lilly’s Zebbound, oral weight loss drugs like TERN-601 offer a convenient pill form.
Building on the success of this early-stage study, Terns plans to initiate a mid-stage clinical trial of TERN-601 next year.
By developing an effective oral obesity treatment, Terns aims to provide a more accessible and convenient solution for individuals struggling with weight loss.
With the global obesity epidemic on the rise, the need for innovative and effective treatments has never been more pressing. Terns’ breakthrough in oral obesity treatment offers new hope for those seeking a more manageable and sustainable weight loss solution.